Aldesleukin Completed Phase 2 Trials for Melanoma / Skin Cancers Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01266603High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI
NCT00509288Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes
NCT00923195Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
NCT00204581Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases